Close Menu

influenza

Health management services and diagnostics firm Alere recently updated investors on the progress of a pair of nucleic acid testing platforms that are currently under development at the company and represent the firm's entrée into molecular diagnostics.

Nanobiosys, a four-year-old South Korean molecular diagnostics firm, has published the first description and validation study of its flagship technology, a fast, portable, and inexpensive fluidic chip-based real-time PCR instrument.

Life Technologies announced this week that it has established a collaborative effort involving researchers from several public health organizations and other organizations to evaluate and adapt an Ion Torrent PGM protocol to sequence the influenza genome for flu tracking and vacc

NEW YORK (GenomeWeb News) – Life Technologies today said that it has established a partnership with researchers aimed at evaluating the use of its Ion Torrent PGM for influenza virus typing.

NEW YORK (GenomeWeb News) – Response Biomedical today said that it has signed a new, nonexclusive deal for Fisher HealthCare to distribute its portfolio of infectious disease tests in the US.

NEW YORK (GenomeWeb News) – A pair of new PLoS ONE studies suggests specific gene expression signatures in host blood samples correspond with symptomatic viral and bacterial infections — information that may ultimately lead to more effective ways of detecting, tracking, and treating such

Cepheid said last week that it has received clearance from the US Food and Drug Administration to market Xpert CT/NG on its GeneXpert system.

NEW YORK (GenomeWeb News) – Two research consortia will receive as much as $52.4 million from the National Institute of Allergy and Infectious Diseases to continue studies using structural genomics to characterize the structures of proteins from a number of dangerous bacterial, protozoan, and vir

BD Diagnostics, a division of Becton Dickinson, and Belgium's Diagenode this week announced the European launch of Diagenode's influenza A and B assay for use on the BD Max molecular testing system.

Focus Diagnostics, a subsidiary of Quest Diagnostics, said this week that the US Food and Drug Administration has granted 510(k) clearance and CLIA moderate-complexity categorization to Focus' Simplexa Flu A/B & RSV direct test on the

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.